The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), ...

Share on Pinterest A drug that has already gained FDA approval for the treatment of ulcerative colitis is also effective in the treatment of Crohn’s, new data suggest. Brothers91/Getty Images ...

Pharmaceutical company Eli Lilly recently released findings of two studies regarding the long-term efficacy and safety of mirikizumab for not only ulcerative colitis, but also Crohn’s disease.

Addressing all aspects of healthcare maintenance in ulcerative colitis (UC) — one of two major types of inflammatory bowel ...

We have access to serum samples via my mentor Jean-Frederic Colombel -- who is the PI [principal investigator] of the PREDICTS study-- up to 10 years before Crohn's disease or ulcerative colitis ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

The studies showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis and Crohn’s disease. Data from the two trials – LUCENT-3 in moderately to ...

P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...